[ad_1]
AstraZeneca vaccine, the only product license application
Pfizer vaccine can be introduced as a ‘special income’ system
As the corona19 vaccine is expected to be vaccinated in Korea from the beginning of next month to next month, the focus is on what will be No.
According to the medical community and quarantine authorities on the 22nd, Korea signed a contract to supply Corona 19 vaccine with four foreign pharmaceutical companies such as AstraZeneca, Janssen, Pfizer and Modena.
Among them, the vaccine that the government initially predicted would be the fastest to introduce is AstraZeneca.
This is because AstraZeneca is the only vaccine that is being reviewed when applying for an article license from the Ministry of Food and Drug Safety. The AstraZeneca vaccine will be approved in February. Pfizer’s vaccine is in the “preliminary review” stage prior to full-scale product approval selection.
However, when looking at the status of vaccines abroad alone, Pfizer vaccines are making headway.
The Pfizer vaccine is being vaccinated in the United States, Israel, the United Kingdom, Saudi Arabia, and Canada.
The countries that have started vaccination against AstraZeneca are India and the UK, and the number is quite small.
In fact, Pfizer’s products will be reviewed promisingly for vaccines to be delivered to Korea in early February through the international ‘Covax Facility’ project. Pfizer Pharmaceutical Korea also announced that it would apply for an article permit from the Ministry of Food and Drug Safety within this month.
However, it is not clear whether the vaccine Pfizer, which has not yet applied for permission, can be vaccinated in early February using the usual procedure.
As a result, there is a possibility that the Pfizer vaccine will be introduced into Korea through the “special import” procedure in addition to product approval.
Special Drug Import is a system that allows the importation of drugs that are not licensed in Korea from abroad to cope with the public health crisis, such as an infectious disease pandemic.
In June last year, the Ministry of Food and Pharmaceutical Safety approved a special import for the Gilead Sciences’ Corona 19 treatment ‘Remdesivir’.
At that time, the Ministry of Food and Pharmaceutical Safety appreciated the effect of remdesivir in reducing the treatment period of severely ill patients with Corona 19. It was also considered that remdesivir was used abroad also for the treatment of Corona 19 .
Kim Sang-bong, head of the Biopharmaceutical Office of the Ministry of Food and Drug Safety, told Yonhap News Agency: “Currently, the KCDC has not confirmed the type of vaccine as Kovax Facility’s Pfizer,” he said.
Yunhap news
[ad_2]
